Results 21 to 30 of about 685,556 (387)
Clinical Chemistry, 1972 A method for estimating the cholesterol content of the serum low-density lipoprotein fraction (Sf0-20) is presented. The method involves measurements of fasting plasma total cholesterol, triglyceride, and high-density lipoprotein cholesterol ...
W. T. Friedewald +2 more
semanticscholar +1 more source
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
Clinical Chemistry, 2020 BACKGROUND Current guidelines target low-density lipoprotein cholesterol (LDL-C) concentrations to reduce atherosclerotic cardiovascular disease (ASCVD) risk, and yet clinical trials demonstrate persistent residual ASCVD risk despite aggressive LDL-C ...
R. Hoogeveen, C. Ballantyne
semanticscholar +1 more source
JACC: Basic to Translational Science, 2020 [Figure: see text]
Michael D. Shapiro, Sergio Fazio
openaire +2 more sources
New England Journal of Medicine, 1999 BACKGROUND Although it is generally accepted that lowering elevated serum levels of low-density lipoprotein (LDL) cholesterol in patients with coronary heart disease is beneficial, there are few data to guide decisions about therapy for patients whose ...
H. Rubins +11 more
semanticscholar +1 more source
Lipid and Lipoprotein Metabolism in Microglia
Frontiers in Physiology, 2020 Microglia, once viewed as static bystanders with limited homeostatic functions, are now considered key players in the development of neuroinflammatory and neurodegenerative diseases.
B. Loving, K. Bruce
semanticscholar +1 more source
HDL and plaque regression in a multiphase model of early atherosclerosis [PDF]
, 2023 Atherosclerotic plaques are accumulations of cholesterol-engorged macrophages in the artery wall. Plaque growth is initiated and sustained by the deposition of low density lipoproteins (LDL) in the artery wall. High density lipoproteins (HDL) counterbalance the effects of LDL by accepting cholesterol from macrophages and removing it from the plaque. In
arxiv +1 more source
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Circulation, 1989 The British Regional Heart Study (BRHS) reported in 1986 that much of the inverse relation of high-density lipoprotein cholesterol (HDLC) and incidence of coronary heart disease was eliminated by covariance adjustment.
D. Gordon +8 more
semanticscholar +1 more source
Lipoprotein(a) and Cardiovascular Disease.
Clinical Chemistry, 2020 BACKGROUND High lipoprotein(a) concentrations present in 10%-20% of the population have long been linked to increased risk of ischemic cardiovascular disease. It is unclear whether high concentrations represent an unmet medical need.
P. Kamstrup
semanticscholar +1 more source
Lipoprotein apheresis to treat elevated lipoprotein (a) [PDF]
Journal of Lipid Research, 2016 An elevated plasma concentration of lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease. Life style modification and currently available drugs either fail to effectively lower plasma Lp(a) levels or do not result in clinical benefit. However, lipoprotein apheresis is very efficient in decreasing Lp(a) concentrations.
Elisa Waldmann, Klaus G. Parhofer
openaire +2 more sources
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
Circulation, 2019 Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration.
M. O’Donoghue +19 more
semanticscholar +1 more source